Comparing the costs, risks, and benefits of competing strategies for the primary prevention of venous thromboembolism

32Citations
Citations of this article
44Readers
Mendeley users who have this article in their library.

Abstract

Systematic cost-effectiveness analyses of regimens used for preventing venous thromboembolism (VTE) are becoming increasingly important for several reasons: the aging of the population, with an accompanying increase in admissions for orthopedic procedures or other surgery; expanded indications for thromboprophylaxis in nonsurgical patients; and the introduction of more expensive new agents that may increase safety and efficacy. At the same time, health care systems are under unprecedented pressure to contain the costs of care, particularly medications. Such economic analyses are made more difficult by the paucity of clinical trials comparing treatment regimens to one another rather than to placebo. Several methodological issues must be kept in mind when evaluating cost-effectiveness analyses of VTE prophylaxis. These include the perspective from which the analysis is performed (eg, the health care system as a whole versus a particular payer), limitations of trial data (eg, artificially short time horizons), and definition of outcomes (eg, flawed definition and grouping together of adverse effects or treatment failures). Quantifying costs across nations and health care systems is problematic as well. Another challenge is the extrapolation of efficacy data from highly monitored study patients to routine practice settings. Nevertheless, cost-effectiveness analyses of VTE treatments conducted in orthopedic surgery, trauma, general surgery, and acute medical settings can help define the relationships among expenditures, adverse outcomes, and patient benefit for particular therapeutic strategies in a variety of clinical situations.

References Powered by Scopus

A comparison of enoxaparin with placebo for the prevention of venous thromboembolism in acutely ill medical patients

1594Citations
N/AReaders
Get full text

Willingness to pay for a quality-adjusted life year: In search of a standard

763Citations
N/AReaders
Get full text

Health economic evaluations: The special case of end-stage renal disease treatment

300Citations
N/AReaders
Get full text

Cited by Powered by Scopus

Prevention of venous thromboembolism: American College of Chest Physicians evidence-based clinical practice guidelines (8th edition)

3892Citations
N/AReaders
Get full text

Deep-vein thrombosis: A United States cost model for a preventable and costly adverse event

64Citations
N/AReaders
Get full text

Prevention of venous thromboembolism in hospitalized patients with cancer

57Citations
N/AReaders
Get full text

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Cite

CITATION STYLE

APA

Avorn, J., & Winkelmayer, W. C. (2004, December 14). Comparing the costs, risks, and benefits of competing strategies for the primary prevention of venous thromboembolism. Circulation. https://doi.org/10.1161/01.CIR.0000150642.10916.ea

Readers' Seniority

Tooltip

PhD / Post grad / Masters / Doc 15

60%

Researcher 5

20%

Professor / Associate Prof. 4

16%

Lecturer / Post doc 1

4%

Readers' Discipline

Tooltip

Medicine and Dentistry 24

75%

Pharmacology, Toxicology and Pharmaceut... 4

13%

Engineering 2

6%

Economics, Econometrics and Finance 2

6%

Save time finding and organizing research with Mendeley

Sign up for free